Aptose Biosciences

Aptose Biosciences

Biotechnology, High BLF Dr, San Diego, , 92130, California, 12770, United States, 11-50 Employees

aptose.com

  • LinkedIn

Who is APTOSE BIOSCIENCES

Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies. ...

Read More

map

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541715 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from APTOSE BIOSCIENCES

Aptose Biosciences Org Chart and Mapping

Diane Greger

Office Manager & Assistant to the CEO

VP-Level
Employees

Elvia Kasitz

Senior Director Human Resources

Marc Wiles

Sr. VP, Regulatory Affairs

Rafael Bejar

Chief Medical Officer, Senior Vice-President

Victor Montalvo-Lugo

Vice President Clinical Operations

Zoey Liu-Imanuel

Director of Regulatory Affairs

Emily Roncase

Clinical Study Manager

Judy Tran

Associate Project Manager

Robby Weissenfels

Senior Clinical Study Associate

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Aptose Biosciences

Answer: Aptose Biosciences's headquarters are located at High BLF Dr, San Diego, , 92130, California, 12770, United States

Answer: Aptose Biosciences's official website is https://aptose.com

Answer: Aptose Biosciences's revenue is $25 Million to $50 Million

Answer: Aptose Biosciences's SIC: 2836

Answer: Aptose Biosciences's NAICS: 541715

Answer: Aptose Biosciences has 11-50 employees

Answer: Aptose Biosciences is in Biotechnology

Answer: Aptose Biosciences contact info: Phone number: Website: https://aptose.com

Answer: Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies. CG-806, our oral mutation-agnostic FLT3/BTK inhibitor, is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkins lymphomas (NHL) who are resistant or intolerant to conventional treatments. CG-806 is also being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML), including the emerging populations resistant to approved targeted therapies. APTO-253, our first-in-class MYC Inhibitor, is being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access